Updated Recommendations for HER2 Testing in Breast Cancer
Author Information
Author(s): Wedad Hanna, Frances P. O’Malley, Penelope Barnes, Richard Berendt, Louis Gaboury, Anthony Magliocco, Norman Pettigrew, Susan Robertson, Sandip Sengupta, Bernard Têtu, Thomas Thomson
Hypothesis
Accurate and standardized testing methods for HER2/neu status are essential for proper classification in breast cancer.
Conclusion
The updated Canadian HER2 testing guidelines aim to improve the accuracy of HER2 testing in breast cancer.
Supporting Evidence
- HER2/neu testing is now the standard of care at the time of breast cancer diagnosis.
- The guidelines are based on the ASCO/CAP guidelines with modifications for Canadian practices.
- Accurate testing methods are crucial for determining the appropriate treatment for breast cancer patients.
Takeaway
Doctors need to test for HER2/neu when someone is diagnosed with breast cancer to help choose the right treatment.
Methodology
The guidelines were developed based on a review of existing ASCO/CAP guidelines and the experiences of Canadian pathologists.
Participant Demographics
Pathologists from various regions in Canada participated in the consensus meeting.
Want to read the original?
Access the complete publication on the publisher's website